Blepharitis News and Research

RSS

A common disorder of the eye, blepharitis, is a condition in which there is visible inflammation in the eyelids. Bacteria causes irritation and the eyelids become red and itchy. Though it does not cause permanent damage to vision, blepharitis causes discomfort to patients. Women in their peri- and post-menopausal stage are more prone to the dysfunction of the meibomian glands.

CDC recommendations and clinical considerations for the treatment of severe Mpox

In a recent article published in the United States (U.S.) Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report, a team of researchers discussed the medical countermeasures and clinical considerations for treating severe manifestations of Mpox.

6 Mar 2023

What are the clinical characteristics and complications of patients with a monkeypox infection?

Researchers described the clinical characteristics and complications of monkeypox virus infections.

29 Aug 2022

Popular eyelash treatments linked to rise in eye infections and emergency procedures

Sun Pharma receives U.S. FDA approval for CEQUA to treat patients with dry eye disease

Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

16 Aug 2018

U-M researchers envision new ways to avoid inappropriate ER use for mild eye problems

Pinkeye isn't a medical emergency. Neither is a puffy eyelid. But a new study finds that nearly one in four people who seek emergency care for eye problems have those mild conditions, and recommends ways to help those patients get the right level of care.

15 Feb 2017

Ophthalmology expert offers tips to help relieve seasonal dry eye

If your eyes feel like the Sahara desert or your vision seems blurrier than usual, don't panic. It may just be seasonal dry eye.

20 Jan 2017

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Philip Chapper & Company Ltd, a UK company with over 40 years’ experience within medical supplies, is to showcase innovative products from new suppliers at the industry’s largest European trade fair.

28 Sep 2015

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."

9 Sep 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.

23 Apr 2014

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company's proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing.

23 Apr 2014

Researchers identify potential therapy for meibomian gland dysfunction

Meibomian gland dysfunction is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.

24 Dec 2013

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.

7 Sep 2012

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012.

31 Jul 2012

InSite Vision first quarter total revenues decrease to $2.3 million

InSite Vision Incorporated today reported financial results for the quarter ended March 31, 2012. Total revenues for the first quarter of 2012 were $2.3 million, a decrease of $0.8 million from the same quarter of 2011.

2 May 2012

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.

26 Sep 2011

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that the first patients have been enrolled and randomized to receive RGN-259 or placebo in its 72-patient, Phase 2 clinical trial in patients with dry eye syndrome.

16 Aug 2011

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome.

29 Jul 2011